Emerging studies suggest this peptide, a dual activator targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , could represent a promising development for obesity management . Early human trials have shown substantial decreases in visceral fat , potentially outperforming current obesity therapies . Despite this, more s